Search

Your search keyword '"Giuseppe Frieri"' showing total 89 results

Search Constraints

Start Over You searched for: Author "Giuseppe Frieri" Remove constraint Author: "Giuseppe Frieri"
89 results on '"Giuseppe Frieri"'

Search Results

1. Association between Corrected QT Interval and C-Reactive Protein in Patients with Inflammatory Bowel Diseases

2. The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine

3. Association between Vasomotor Rhinitis and Irritable Bowel Syndrome

4. Prophylactic Treatment with Vedolizumab in the Prevention of Postoperative Recurrence (POR) in High-Risk Crohn’s Patients

5. Sleep disorders related to nutrition and digestive diseases: a neglected clinical condition

6. Duodenal lymphocytosis in functional dyspepsia

7. Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?

8. Inflammatory bowel disease: New insights into the interplay between environmental factors and pparγ

9. AF.41 THE PROGNOSTIC VALUE OF ENDOSCOPIC MAYO SCORE 0 VERSUS 1 IN PATIENTS WITH ULCERATIVE COLITIS IN STEROID-FREE CLINICAL REMISSION: A SYSTEMATIC REVIEW AND METAANALYSIS

10. AF.61 PROSPECTIVE, OBSERVATIONAL STUDY OF PROPHYLACTIC VEDOLIZUMAB TREATMENT IN PREVENTING POSTOPERATIVE RECURRENCE (POR) IN HIGH-RISK CROHN’S PATIENTS

11. Association between Corrected QT Interval and C-Reactive Protein in Patients with Inflammatory Bowel Diseases

12. Surrogate Fecal Biomarkers in Inflammatory Bowel Disease: Rivals or Complementary Tools of Fecal Calprotectin?

13. Subtypes of chronic gastritis in patients with celiac disease before and after gluten‐free diet

14. Mastocytic enterocolitis: Increase of mast cells in the gastrointestinal tract of patients with chronic diarrhea

15. Is fecal calprotectin an accurate marker in the management of Crohn's disease?

16. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)

17. Topical Aminosalicylates and Histologic Healing in Ulcerative Colitis

18. Association between vasomotor rhinitis and irritable bowel syndrome

20. Metabolic Alterations in Celiac Disease Occurring after Following a Gluten-Free Diet

22. IgG4-Related Disease Mimicking Crohn's Disease: A Case Report and Review of Literature

23. The prognostic value of histology in ulcerative colitis in clinical remission with mesalazine

24. Nanotechnology in the treatment of inflammatory bowel diseases

25. Can Nrf2 Modulate the Development of Intestinal Fibrosis and Cancer in Inflammatory Bowel Disease?

26. The role on endoscopy in alcohol-related diseases

27. Treatment of inflammatory bowel diseases: To heal the wound or to heal the sick?

28. Early acid perception in NERD

30. The long journey of salicylates in ulcerative colitis: The past and the future

31. Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease

32. Non-Celiac Gluten Sensitivity among Patients Perceiving Gluten-Related Symptoms

33. Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis

34. GI distension in severe ulcerative colitis

35. The high medical cost of celiac disease missed diagnosis: is it cheaper to suspect it in time?

36. [Untitled]

37. Polyunsaturated fatty acid dietary supplementation: An adjuvant approach to treatment of Helicobacter pylori infection

38. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment

39. Prevention of post-operative recurrence of Crohn’s disease requires adequate mucosal concentration of mesalazine

40. Circulating soluble factor-inhibiting natural killer (NK) activity of fresh peripheral blood mononuclear cells (PBMC) from inflammatory bowel disease (IBD) patients

41. [Untitled]

42. Acute Colitis Following Colonoscopy

43. [Untitled]

44. Colonic involvement in celiac disease and possible implications of the sigmoid mucosa organ culture in its diagnosis

45. Corrigendum to 'Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease' [Dig. Liver Dis. 48 (2016) 360–370]

46. Ulcerative colitis: Rectal dilations in a patient with refractory diarrhea

47. Gastric and Duodenal Juxtamucosal pH and Helicobacter pylori

48. P.06.6 SUBTYPES OF CHRONIC GASTRITIS IN PATIENTS WITH COELIAC DISEASE BEFORE AND AFTER GLUTEN-FREE DIET

49. P.09.11 ASSOCIATION BETWEEN COLORECTAL POLYPS AND COLONIC DIVERTICULOSIS

50. Education and Imaging: gastrointestinal: eosinophilic ascites

Catalog

Books, media, physical & digital resources